A172-luc Orthotopic Mouse Model Service for Brain Cancer

The A172-luc orthotopic mouse model delivers a human glioblastoma multiforme platform characterized by EGFR amplification, chromosome 7 polysomy, and mesenchymal differentiation, enabling real-time bioluminescence tracking of tumor growth and therapeutic response within the immunodeficient murine brain. Alfa Cytology constructs, validates, and manages this human xenograft glioma system with integrated imaging and comprehensive neuropathological endpoints, supplying researchers with reproducible preclinical data to advance targeted therapy and drug penetration programs.

Overview of A172-luc Orthotopic Mouse Model for Brain Cancer

The A172-luc orthotopic model is established by stereotactically implanting luciferase-transduced A172 human glioblastoma cells into the striatum of immunodeficient nude mice, generating an intracranial tumor that recapitulates the epithelial-like morphology, high cellularity, and infiltrative growth patterns characteristic of human glioblastoma multiforme. Originally isolated from a 53-year-old male patient, the A172 line exhibits a hypertriploid karyotype with polysomy of chromosome 7 and EGFR amplification driven by 7p11.2 duplication, resulting in novel topologically associating domains that enhance oncogenic enhancer-promoter interactions. The stable integration of firefly luciferase permits non-invasive, longitudinal bioluminescence imaging of tumor burden deep within the brain parenchyma, providing a quantitative surrogate for monitoring engraftment, exponential growth, and treatment-induced regression without serial magnetic resonance imaging or repeated terminal sampling.

Fig 1. circPRKCI shRNA inhibits A172 glioma cell growth, survival, proliferation and migration. (Zhang, Xuebang, et al., 2019)

Histologically, A172-luc tumors display features consistent with high-grade glioma, including dense cellularity, nuclear polymorphism, and florid microvascular proliferation accompanied by pro-angiogenic factor secretion such as VEGF, FGF2(b), and TGF-β1. The cell line is further distinguished by its mesenchymal gene expression profile, marked by CD90, CD105, FAP, and tenascin expression, alongside cancer stem cell-like properties regulated by Heat Shock Factor 1 (HSF1) and SOX2. With documented sensitivity to temozolomide and responsiveness to connexin-43 mimetic peptide sensitization, the A172-luc model occupies a unique position for evaluating EGFR-targeted inhibitors, metabolic disruptors, blood-brain barrier-penetrant agents, and combination radio-chemotherapy strategies in a human-relevant preclinical setting.

Cell Line Information: A172-luc

A172-luc is a luciferase-reporter derivative of the A172 human glioblastoma cell line, generated through lentiviral transduction to stably express firefly luciferase for in vivo bioluminescent tracking. The parental A172 line was originally isolated from a glioblastoma multiforme tumor removed from a 53-year-old male patient and has been extensively characterized as a representative model of mesenchymal-subtype, EGFR-amplified glioblastoma. Key attributes are summarized below:

Our Services

Our ServicesOur ServicesAlfa Cytology offers comprehensive A172-luc orthotopic glioblastoma model services encompassing stereotactic surgical implantation in immunodeficient hosts, longitudinal bioluminescence imaging, magnetic resonance imaging integration, and detailed neuropathological endpoint analysis with EGFR and mesenchymal marker immunohistochemistry. Every study is conducted within fully accredited vivarium facilities under IACUC oversight, ensuring scientific precision, ethical compliance, and complete data traceability from model construction through final report delivery.

Workflow of A172-luc Orthotopic Mouse Model Construction

Construction of the A172-luc orthotopic glioblastoma model employs stereotactic intracranial injection to deliver human tumor cells into the striatum of immunodeficient nude mice, ensuring reproducible engraftment, minimal surgical morbidity, and consistent growth kinetics. The protocol integrates pre-operative analgesia, aseptic stereotactic surgery, controlled cell infusion, and longitudinal bioluminescence monitoring, as detailed below:

1. Cell Preparation and Batch Validation: A172-luc cells are expanded under low-passage conditions (passage 3–8) in high-glucose DMEM supplemented with 10% FBS to preserve EGFR-amplified phenotype and mesenchymal differentiation. Viability is confirmed by trypan blue exclusion (>95% required), and luciferase expression is validated via in vitro bioluminescence assay to ensure uniform reporter signal intensity across the batch.
2. Animal Selection and Acclimation: Female athymic nude mice (Nu/Nu, 6–8 weeks old) are selected to accommodate human xenograft engraftment. A one-week acclimation period is observed under specific-pathogen-free housing, with daily health monitoring and body weight recording to establish individual baseline parameters.
3. Pre-Operative Analgesia and Anesthesia: Mice receive pre-operative analgesia comprising buprenorphine (0.1 mg/kg) and carprofen (5 mg/kg) subcutaneously. General anesthesia is induced and maintained with isoflurane (3% induction, 1.5–2% maintenance) delivered via nose cone, with continuous respiration and body temperature monitoring throughout the procedure.
4. Surgical Site Preparation: The scalp is shaved and depilatory cream is applied to remove fur, followed by sterilization with iodine solution. The mouse is secured in a stereotaxic frame with ear bars and a bite bar, and a single midline incision is made to expose the skull surface and identify the bregma landmark.
5. Craniotomy and Dural Exposure: A small burr hole is drilled at the predetermined stereotactic coordinates (anteroposterior +1 mm, mediolateral +2 mm relative to bregma) using a high-speed microdrill under constant saline cooling. The dura mater is carefully pierced to expose the underlying parenchyma without causing cortical trauma or hemorrhage.
6. Tumor Cell Injection: A 10 µL Hamilton syringe fitted with a glass micropipette is lowered through the burr hole to a depth of −3 mm relative to bregma, targeting the right striatum. A172-luc cells (1 × 10⁵) in 2 µL PBS are delivered using a micropump injector over 2 minutes at a constant infusion rate. A single-cell suspension is essential to prevent clumping and ensure uniform tumor seeding within the striatal parenchyma.
7. Needle Retraction and Wound Closure: The needle is left in place for an additional 2 minutes to prevent retrograde flow along the injection tract, then withdrawn slowly over 1 minute to minimize cell tracking. The scalp incision is closed with surgical sutures or tissue adhesive, and the mouse is transferred to a heated recovery chamber.
8. Post-Operative Care and Monitoring: Mice receive carprofen-supplemented drinking water (33 µg/mL) for 72 hours post-surgery and are monitored twice daily for neurological deficits, body weight, and wound integrity. Animals are allowed to recover for a minimum of 3 days before initiation of any imaging or treatment protocol.
9. Bioluminescence Imaging and Tumor Monitoring: Starting at day 4–7 post-implantation, tumor establishment and growth are monitored via IVIS Spectrum or equivalent bioluminescence imaging system following intraperitoneal D-luciferin administration (150 mg/kg). Regions of interest are drawn over the cranial vault, and photon flux (photons/sec/cm²/sr) is quantified to generate longitudinal growth curves for each animal.
10. Endpoint Analysis and Neuropathology: At study termination, mice are humanely euthanized and brains are excised, weighed, and processed for formalin-fixed paraffin embedding. Coronal serial sections are stained with H&E for morphological assessment, and immunohistochemistry is performed for Ki67, EGFR, CD31, GFAP, human-specific cytokeratins, and SOX2 to confirm tumor origin, proliferative index, receptor expression, vascular density, and stemness marker status.

Fig 2. A172-luc Orthotopic Mouse Model construction workflow.

Case Study-A172-luc Orthotopic Mouse Model Development

In a representative preclinical engagement, the A172-luc orthotopic model was deployed to evaluate the efficacy of a novel EGFR-targeted therapeutic agent in combination with temozolomide against glioblastoma multiforme. Following stereotactic implantation and confirmation of engraftment by bioluminescence imaging within the first week, cohorts were randomized to receive either the combination regimen, monotherapy arms, or vehicle control. Longitudinal BLI revealed distinct growth trajectories across treatment groups, with the combination cohort demonstrating attenuated photon flux accumulation relative to both monotherapy and control arms. Terminal neuropathological analysis showed reduced intracranial tumor burden, diminished microvascular proliferation, and decreased EGFR phosphorylation in treated animals, alongside preserved peritumoral brain architecture in responders. These preclinical findings informed the regimen's mechanism-of-action hypothesis and supported advancement toward subsequent pharmacology and toxicology studies.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your A172-luc orthotopic glioblastoma program provides access to a human-xenograft-focused, quality-driven preclinical infrastructure optimized for intracranial tumor research and receptor-targeted therapy evaluation. Our core differentiators include:

• Extensive experience with human glioblastoma xenograft model development, with optimized stereotactic surgical protocols that achieve consistent striatal engraftment and predictable tumor kinetics in immunodeficient nude mice.
• Integrated bioluminescence and small-animal MRI imaging platforms enabling non-invasive, quantitative longitudinal tracking of intracranial tumor dynamics without introducing serial sacrifice artifacts into your dataset.
• Rigorous cell banking and authentication procedures, encompassing STR profiling, mycoplasma screening, luciferase expression validation, and EGFR amplification confirmation to ensure model fidelity and batch-to-batch reproducibility.
• Adaptable study architectures supporting single-agent screening, combination radio-chemotherapy regimens, EGFR inhibitor evaluation, anti-angiogenic drug profiling, and blood-brain barrier penetration assessment tailored to your therapeutic modality.
• Comprehensive neuropathological endpoint capabilities including digital histopathology, immunohistochemistry for EGFR and mesenchymal markers, multiplex immunofluorescence, and human-specific marker confirmation to generate mechanistic insights alongside efficacy data.
• A dedicated scientific project management team providing transparent milestone reporting, timeline accountability, and direct consultation from protocol design through final data package delivery.

Contact Us

Whether your program targets glioblastoma with a novel EGFR inhibitor, an anti-angiogenic agent, a metabolic disruptor, or a blood-brain barrier-penetrant small molecule, Alfa Cytology is equipped to accelerate your preclinical development with our A172-luc orthotopic glioblastoma expertise. Reach out to us today to discuss your study design, review our imaging and surgical capabilities, and receive a customized proposal aligned with your scientific objectives and timeline. Our neuro-oncology team looks forward to collaborating with you to generate the robust, translationally relevant data your pipeline demands.

For research use only. Not intended for any clinical use.